This study by Anderson et al. (JAMA Oncology, 2017) sought to determine if cancer diagnosis and treatment in adolescence and young adulthood (15-39 years of age) impairs reproductive outcomes for female cancer survivors.
Retrospective Cohort Study
2,598 live births born to adolescent and young adulthood (AYA) cancer survivors were compared to 1,299 randomly chosen births matched for maternal age and birth year. Outcomes compared included preterm birth, low birth weight, small-for-gestational age, C-sections, and low Apgar score (<7). AYA cancer survivors had significantly increased rates of preterm birth, low birth weight, and C-sections compared to the comparison cohort. These higher rates were most closely associated with intrapartum diagnoses. Cancers more highly associated with preterm birth and low birth weight included breast, gynecological cancers, and non-Hodgkin lymphoma. Rates of small for gestational age and low Apgar scores were not significantly different between the two groups. The authors suggest closer surveillance of AYA cancer survivors.
Birth Outcomes Among Adolescent and Young Adult Cancer Survivors
Please log in to access OBGFirst and the 2T Ultrasound Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
